{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:39:40Z","timestamp":1784176780771,"version":"3.55.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Service"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018754","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Subjective loss of response immediately prior to routine TNFi therapy can occur in axial spondyloarthritis (axSpA). We investigated clinical outcomes in patients taking the first three licenced TNFis and correlated this with recurrence of MRI bone marrow oedema (MRI-BMO).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Proof-of-concept study including axSpA patients established on etanercept (ETA), adalimumab (ADA) or infliximab (IFX) reporting symptom deterioration prior to next dose. MRI\/clinical data were collected prior to scheduled dose (v1), 4\u2009days post-dose (v2) and at the time of patient-reported symptom return (v3). MRI spine\/sacroiliac joints utilizing 3\u2009T were scored using the semi-quantitative Leeds MRI scoring system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 113 clinical assessments and MRIs were performed in 38 participants (ADA\u2009=\u200916, ETA\u2009=\u200912, IFX\u2009=\u200910), mean age 42.1\u2009years\u2009\u00b1\u200924.4(2SD, n\u2009=\u200938), 71.1% male (n\u2009=\u200927\/38), 69.7% HLA-B27 positive (n\u2009=\u200923\/33). At v1, all patients had high disease activity [ASDAS-CRP\u2009=\u20093 (2.7\u20133.7)] and 57.9% had MRI-BMO (number of MRI-BMO: ETA\u2009=\u200926, ADA\u2009=\u200959, IFX\u2009=\u200928). Improved clinical responses were seen at v2 [ASDAS-CRP \u22120.41(\u22120.81\u2009\u2212\u20090.30), P =0.018; BASDAI \u22120.58(\u22122.2\u2009\u2212\u20090.52), P =0.024]. Despite just a 4-day interval between v1 and v2, a numerical reduction in MRI-BMO lesions between v1\/v2 was observed (ETA\u2009=\u2009\u22126, ADA\u2009=\u2009\u221210, IFX\u2009=\u2009\u22123). By v3, comparatively fewer new BMO lesions were detected in the ETA and ADA groups compared with IFX (ETA\u2009=\u2009\u22121, ADA\u2009=\u2009+3, IFX\u2009=\u2009+8), although the numbers were too small to enable testing for statistical significance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Short-lived fluctuations in MRI-BMO were commoner with longer-acting agents and corresponded with subjective loss of clinical response before next scheduled TNFi dose. Larger studies are needed to confirm the possible pathogenic implications of this phenomenon.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab571","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T19:11:58Z","timestamp":1626376318000},"page":"SI86-SI91","source":"Crossref","is-referenced-by-count":4,"title":["Subjective loss of clinical response to TNFi in axSpA relates to recurrence of MRI bone marrow oedema particularly with long-acting agents"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-2621","authenticated-orcid":false,"given":"Stephanie R","family":"Harrison","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ansell","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Department of Rheumatology, Bradford Teaching Hospitals, St Luke\u2019s Hospital, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R","family":"Mathieson","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"},{"name":"Department of Rheumatology, Bradford Teaching Hospitals, St Luke\u2019s Hospital, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Merashli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, American University Hospital, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Busquets-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital General de Granollers, Granollers, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"2022041816211632600_keab571-B1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2022041816211632600_keab571-B2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","article-title":"Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice","volume":"21","author":"Lindstr\u00f6m","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022041816211632600_keab571-B3","year":"2002"},{"key":"2022041816211632600_keab571-B4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical pharmacokinetics and use of infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"2022041816211632600_keab571-B5","year":"2021"},{"key":"2022041816211632600_keab571-B6","first-page":"473","article-title":"Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis","author":"Aybay","year":"2006"},{"key":"2022041816211632600_keab571-B7","first-page":"1759720X20906040","article-title":"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: structured literature review","volume":"12","author":"Baraliakos","year":"2020","journal-title":"Ther Adv Musculoskelet Disord"},{"key":"2022041816211632600_keab571-B8","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.24024","article-title":"Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years","volume":"58","author":"Bennett","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022041816211632600_keab571-B9","year":"2016"},{"key":"2022041816211632600_keab571-B10","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022041816211632600_keab571-B11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/art.24493","article-title":"Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondyloarthritis","volume":"60","author":"Bennett","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022041816211632600_keab571-B12","first-page":"S175","article-title":"Etanercept treatment in resistant spondyloarthropathy: imaging, duration of effect and efficacy in reintroduction","volume":"20","author":"Marzo-Ortega","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2022041816211632600_keab571-B13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/annrheumdis-2019-215553","article-title":"Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged &lt;45 years","volume":"79","author":"Baraliakos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022041816211632600_keab571-B14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.080871","article-title":"The natural course of radiographic progression in ankylosing spondylitis - evidence for major individual variations in a large proportion of patients","volume":"36","author":"Baraliakos","year":"2009","journal-title":"J Rheumatol"},{"key":"2022041816211632600_keab571-B15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3899\/jrheum.170171","article-title":"Short-term repeat magnetic resonance imaging scans in suspected early axial spondyloarthritis are clinically relevant only in HLA-B27-positive male subjects","volume":"45","author":"Sengupta","year":"2018","journal-title":"J Rheumatol"},{"key":"2022041816211632600_keab571-B16","doi-asserted-by":"crossref","first-page":"e001093","DOI":"10.1136\/rmdopen-2019-001093","article-title":"5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort","volume":"6","author":"Madari","year":"2020","journal-title":"RMD Open"},{"key":"2022041816211632600_keab571-B17","doi-asserted-by":"crossref","first-page":"e14620","DOI":"10.1097\/MD.0000000000014620","article-title":"A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients","volume":"98","author":"Yang","year":"2019","journal-title":"Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab571\/40416809\/keab571.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/SI\/SI86\/43391597\/keab571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/SI\/SI86\/43391597\/keab571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T16:22:08Z","timestamp":1650298928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/SI\/SI86\/6323373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":17,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2021,7,17]]},"published-print":{"date-parts":[[2022,4,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab571","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,7,17]]}}}